Psyence Labs takes 49.75% of Psyence Biomedical in $8.99M share swap
What's the deal? Psyence LabsDealroom has a profile for this one. Try Dealroom → has acquired 1,497,500 common shares of Psyence BiomedicalDealroom has a profile for this one. Try Dealroom →, a Nasdaq-listed Ontario corporation, lifting its stake to 49.75%. The all-stock transaction, completed October 1, 2026, carried aggregate non-cash consideration of $8,985,000.
How it works: The deal was a share-for-share swap of equal agreed value, with no cash exchanged. Psyence Biomedical issued the shares at a deemed price of $6.00 each; in return, Psyence Labs issued 3,473 of its own ordinary shares at an implied equity valuation of $60 million.
Why now? The swap builds on an earlier position. Psyence Labs acquired 1,146,159 shares in February 2026 under a put option agreement, and the latest tranche brings its total holding to 2,643,659 shares.
What changes? Psyence Labs now holds sole voting and dispositive power over all its shares and "may be deemed to be an affiliate and control person of the Issuer," according to the filing. The company stopped just short of majority control.
The catch: The agreement imposes standstill restrictions. For the duration of its ownership, Psyence Labs is barred from further acquisitions, proxy solicitation, or efforts to influence the board or governance without prior consent.
The signal: By pairing stock rather than cash and stopping below 50%, the parties structure control while preserving Psyence Biomedical's standing. The valuations — $6.00 per target share against a $60 million implied value for Psyence Labs — were drawn from an independent third-party valuation, setting a reference point for any future moves.
Read more: kalkine.com
Image credit: Generated with Gemini
